



Correction: Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy

Danjie He¹ · Yudong Zhang² · Shuiqing He¹ · Yuzhuo Zhang³ · Keyao Dai³ · Cheng Xu¹ · Ying Huang¹ 

Published online: 28 February 2024

© The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO) 2024

Correction: Clinical and Translational Oncology

<https://doi.org/10.1007/s12094-023-03344-w>

Table 1 was missing from this article and should have appeared as shown below.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s12094-023-03344-w>.

✉ Cheng Xu
xucheng@sysucc.org.cn

✉ Ying Huang
huangying@sysucc.org.cn

¹ Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, People's Republic of China

² Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510062, People's Republic of China

³ Guangzhou Medical University, Guangzhou, Guangdong 511436, People's Republic of China

Table 1 Association of baseline characteristics on progression-free survival

	No	%	Univariate analysis		Multivariable analysis	
			HR (95% CI)	<i>p</i> value	HR (95% CI)	<i>p</i> value
Sex						
Males	145	78	Reference			
Females	41	22	0.66 (0.40–1.10)	0.109	–	–
Age						
≤45	86	46	Reference			
>45	100	54	0.91 (0.62–1.34)	0.633	–	–
T status						
T0–2	106	57	Reference			
T3–4	80	43	1.13 (0.77–1.68)	0.528	–	–
N status						
N0–2	153	82	Reference			
N3	33	18	1.41 (0.85–2.32)	0.180	–	–
M status						
M0	53	28	Reference			
M1	133	72	1.28 (0.81–2.00)	0.286	–	–
Primary region progress						
No	101	54	Reference			
Yes	85	46	0.81 (0.55–1.20)	0.301	–	–
Lung metastasis						
No	129	69	Reference			
Yes	57	31	0.92 (0.60–1.40)	0.687	–	–
Liver metastasis						
No	135	73	Reference		Reference	
Yes	51	27	2.04 (1.36–3.04)	0.001	1.79 (1.15–2.79)	0.011*
Bone metastasis						
No	125	67	Reference			
Yes	61	33	1.59 (1.07–2.37)	0.020	–	–
Distant lymph node metastases						
No	144	77	Reference		Reference	
Yes	42	23	1.58 (1.03–2.42)	0.035	1.09 (0.67–1.78)	0.727
EBV-DNA, copies/ml						
≤4000	119	64	Reference			
>4000	67	36	1.55 (1.05–2.29)	0.027	–	–
EBV-DNA copies after one cycle						
Always negative	33	18	Reference		Reference	
Turned negative	80	43	1.17 (0.63–2.17)	0.614	0.94 (0.49–1.79)	0.848
Decrease	66	35	2.19 (1.20–4.01)	0.011	1.41 (0.74–2.71)	0.297
Increase	7	4	6.14 (2.32–16.24)	0.000	3.40 (1.20–9.61)	0.021*
Lymphocyte to monocyte ratio						
≤1.8	39	21	Reference		Reference	
>1.8	147	79	0.51 (0.33–0.78)	0.002	0.64 (0.40–1.04)	0.070
Albumin, g/L						
≤40	32	17	Reference		Reference	
>40	154	83	0.47 (0.30–0.74)	0.001	0.68 (0.40–1.16)	0.160
Platelet, 10⁹/L						
≤300	133	72	Reference		Reference	
>300	53	28	1.97 (1.32–2.92)	0.001	1.73 (1.12–2.69)	0.014*

Table 1 (continued)

	No	%	Univariate analysis		Multivariable analysis	
			HR (95% CI)	<i>p</i> value	HR (95% CI)	<i>p</i> value
Lactate dehydrogenase, U/L						
≤ 180	97	52	Reference		Reference	
180 < and ≤ 360	72	39	1.86 (1.22–2.84)	0.004	1.78 (1.15–2.77)	0.011*
> 360	17	9	4.42 (2.46–7.95)	0.000	1.63 (0.78–3.41)	0.198
Anti-PD-1 antigens						
Toripalimab	75	40	Reference			
Camrelizumab	48	26	1.03 (0.64–1.66)	0.915	–	–
Tislelizumab	44	24	1.03 (0.62–1.73)	0.888	–	–
Sintilimab	16	9	1.12 (0.54–2.30)	0.764	–	–
Nivolumab	1	1	0.86 (0.12–6.29)	0.881	–	–
Pembrolizumab	2	1	1.05 (0.14–7.61)	0.965	–	–

Variables with *p* value < 0.01 in the univariate analysis were included in the multivariable analysis

HR hazard risk, *CI* confidence interval

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.